Real-world evidence for chronic lymphocytic leukemia in the era of targeted therapies Review


Authors: Islam, P.; Mato, A. R.
Review Title: Real-world evidence for chronic lymphocytic leukemia in the era of targeted therapies
Abstract: The landscape of chronic lymphocytic leukemia has transformed in the era of small molecule inhibitor targeted therapies. While randomized controlled trials remain the criterion standard in evaluating new therapies, they are often unable to keep pace with the clinical questions that arise during the use of novel agents. Real-world evidence is generated through analysis of data such as electronic medical records, payer claims, and patient registry databases and can provide invaluable information to supplement randomized controlled trials, such as outcomes in patient populations excluded from clinical trials, rates of discontinuation or dose reductions in clinical practice, survival outcomes, and optimal sequencing of novel agents. This review aims to discuss major findings from recent, relevant, real-world evidence publications that have greatly informed our understanding of chronic lymphocytic leukemia as it is treated in clinical practice.
Journal Title: The Cancer Journal
Volume: 25
Issue: 6
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2019-11-01
Start Page: 442
End Page: 448
Language: English
DOI: 10.1097/ppo.0000000000000407
PUBMED: 31764126
PROVIDER: scopus
PMCID: PMC7427105
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Anthony R Mato
    137 Mato